RevolKa Ltd., a biotech company based in Sendai, Japan, has raised $1.4 million in additional Series A funding. The company uses AI technology through its aiProtein platform to design and improve proteins.
The funding round was led by current investors D3 LLC and TOHOKU University Venture Partners, with support from DEEPCORE Inc.
The company plans to use the money to advance its drug research for rare diseases and support partnerships with other organizations.
RevolKa has created a special platform called aiProtein, which uses artificial intelligence (AI) to help design and improve proteins. Proteins are chains of amino acids that fold into complex shapes to perform different bodily jobs.
Scientists still don’t fully understand how a protein’s structure and function are related, which makes it hard to design new proteins.
RevolKa’s AI is trained to know how a protein’s sequence affects what it does, making it easier to create proteins with specific functions.
aiProtein can improve several features of a protein at the same time. This makes it useful for creating new proteins that can be used in medicine and industry.
About RevolKa Ltd.
RevolKa is a biotechnology company started in April 2021 by experts in biotechnology and artificial intelligence. The company aims to improve human health by creating new proteins for medicines and industrial uses using their special aiProtein technology.
The name “RevolKa” comes from the Latin word for evolution, “evolutio,” and the Ainu word for “raise,” “reska.” RevolKa is based in Sendai, Japan, where its headquarters and labs are located.
Read more- Starlink Launches in Bangladesh to Improve Reliable Internet Access
